IMPACT OF RACE AND ETHNICITY ON PROGNOSTIC MODELS OF OUTCOMES IN PRIMARY SCLEROSING CHOLANGITIS
Christopher L. Bowlus(University of California, Davis), Brad H. Pollock(University of California, Davis), Joseph Zepeda(University of California, Davis), David N. Assis(Yale University), Craig Lammert(Indiana University – Purdue University Indianapolis), K. Rajender Reddy(Hospital of the University of Pennsylvania), Stuart C. Gordon(United States Department of Veterans Affairs), James L. Boyer(Celldex Therapeutics (United States)), Jialin Wu(Sun Yat-sen University), Cynthia Levy(University of Miami), Joseph Ahn(Mayo Clinic), Stacey Prenner(University of Pennsylvania), Lisa Forman(Center for Clinical Research (United States)), David S. Goldberg(University of Miami), Marina G. Silveira, Barry Schlansky(Kaiser Permanente)
Unknown
January 1, 2020
Cited by 0
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
The association between hepatitis C infection and survival after orthotopic liver transplantation
|Gastroenterology|2002|1k